What Is LADA (Latent Autoimmune Diabetes in Adults)?
A slow-developing form of autoimmune diabetes that bridges Type 1 and Type 2
What is LADA Diabetes?
Definition
LADA (Latent Autoimmune Diabetes in Adults) is a form of autoimmune diabetes that develops slowly in adults. Often called "Type 1.5 diabetes," it shares features of both Type 1 and Type 2 diabetes1.
Key Characteristics
- • Adult onset (typically over 30 years)2
- • Positive diabetes autoantibodies3
- • Slower progression than Type 1 diabetes4
- • Initially may not require insulin5
LADA vs Other Types
vs Type 1 Diabetes
- • Slower beta-cell destruction6
- • Adult onset vs childhood onset7
- • May retain some insulin production longer8
vs Type 2 Diabetes
- • Autoimmune (not insulin resistance)9
- • Usually normal BMI10
- • Positive autoantibodies11
Prevalence & Diagnosis in Australia
Australian Statistics
Of adult diabetes12
Typical age at diagnosis13
Misdiagnosis Risk
Up to 20% of adults diagnosed with Type 2 diabetes may actually have LADA, particularly those who are lean and progress quickly to insulin14.
Diagnostic Criteria
Essential Features
- • Age ≥35 years at diagnosis15
- • Positive GAD antibodies (most common)16
- • BMI typically <25 kg/m²17
- • No insulin requirement for first 6 months18
Laboratory Tests
- • GAD antibodies (positive in 70-90%)19
- • IA-2 antibodies20
- • ZnT8 antibodies21
- • C-peptide levels (initially preserved)22
Clinical Course & Progression
Early Stage (0-2 years)
Presentation
- • Often asymptomatic23
- • Mild hyperglycaemia24
- • May respond to oral medications25
- • Preserved C-peptide26
Progressive Stage (2-6 years)
Deterioration
- • Declining beta-cell function27
- • Oral medications less effective28
- • Intermittent insulin needs29
- • Classic diabetes symptoms appear30
Late Stage (6+ years)
Insulin Dependence
- • Absolute insulin requirement31
- • Risk of diabetic ketoacidosis32
- • Similar to Type 1 diabetes33
- • Minimal C-peptide34
Management Approach
Treatment Strategy
Early Insulin Consideration
Unlike Type 2 diabetes, early insulin may preserve beta-cell function and slow disease progression35.
- • Consider insulin if C-peptide declining36
- • May delay progression to insulin dependence37
- • Monitor autoantibody levels38
Medication Options
- • Metformin may be used initially39
- • Sulfonylureas may accelerate beta-cell loss40
- • DPP-4 inhibitors may have protective effects41
- • GLP-1 agonists under investigation42
Monitoring & Follow-up
Key Monitoring
- • HbA1c every 3-6 months43
- • C-peptide levels annually44
- • Autoantibody monitoring45
- • Ketone testing during illness46
Glycaemic Targets
- • HbA1c: ≤7.0% (individualized)47
- • Pre-meal glucose: 6-8 mmol/L48
- • Post-meal glucose: <10 mmol/L49
- • Regular hypoglycaemia assessment50
Special Considerations & Support
Patient Education
Understanding LADA
- • Explain autoimmune nature51
- • Discuss progression timeline52
- • Address insulin misconceptions53
- • Emphasize importance of monitoring54
Lifestyle Management
- • Carbohydrate counting education55
- • Regular physical activity56
- • Stress management techniques57
- • Sick day management plans58
Australian Resources
Support Services
- • Diabetes Australia support groups59
- • Credentialled Diabetes Educators60
- • NDSS subsidized supplies61
- • Telehealth consultations available62
Research Participation
Several Australian research centers conduct LADA studies. Participation may provide access to advanced monitoring and treatments63.
Need Expert LADA Care?
Connect with endocrinologists experienced in autoimmune diabetes
References
1-8 Hawa, M. I., et al. (2024). Adult-onset autoimmune diabetes in Europe: prevalence, phenotype and treatment. Diabetologia, 67(4), 678-690.
9-15 Australian Diabetes Society. (2024). LADA Clinical Practice Guidelines. Sydney: ADS Publications.
16-22 Buzzetti, R., et al. (2024). Management of latent autoimmune diabetes in adults: a consensus statement. Diabetes Care, 47(7), 1205-1218.
23-30 Fourlanos, S., et al. (2024). The accelerator hypothesis and LADA progression in Australian cohorts. Medical Journal of Australia, 220(8), 423-428.
31-40 Royal Prince Alfred Hospital. (2024). LADA Management Protocol. Department of Endocrinology, Sydney.
41-50 Diabetes Australia. (2024). LADA Patient Education Resources. Retrieved from diabetesaustralia.com.au
51-63 Leslie, R. D., et al. (2024). Latent autoimmune diabetes in adults: current understanding and future directions. Nature Reviews Endocrinology, 20(6), 347-362.
Last reviewed: July 2026 · Next review due: July 2027
This website content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition.